<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03843359</url>
  </required_header>
  <id_info>
    <org_study_id>208850</org_study_id>
    <nct_id>NCT03843359</nct_id>
  </id_info>
  <brief_title>Phase 1 First Time in Human (FTIH), Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety, tolerability, and preliminary clinical activity and&#xD;
      establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered&#xD;
      (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts&#xD;
      will consist of a dose escalation phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">January 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>In Part 1A, escalating doses of GSK3745417 will be evaluated and in Part 2A, escalating doses of GSK3745417 in combination with dostarlimab will be evaluated as guided by the Bayesian Logistic Regression Model (BLRM). Part 1B (monotherapy dose expansion) &amp; Part 2B (combination therapy dose expansion) will be planned upon conclusion of dose escalation parts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an Open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1A and 2A: Number of participants achieving dose-limiting toxicity (DLT)</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1A and 2A: Number of participants with adverse events (AEs) and serious adverse events (SAEs) by severity</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1A: GSK3745417 concentrations in plasma following administration of GSK3745417 alone</measure>
    <time_frame>Up to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1A: Maximum observed concentration (Cmax) following administration of GSK3745417 alone</measure>
    <time_frame>Up to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1A: Area under the concentration-time curve (AUC) following administration of GSK3745417 alone</measure>
    <time_frame>Up to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1A: Apparent terminal phase half-life (t1/2) following administration of GSK3745417 alone</measure>
    <time_frame>Up to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: GSK3745417 concentrations in plasma following administration of GSK3745417 in combination with dostarlimab</measure>
    <time_frame>Up to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: Cmax following administration of GSK3745417 in combination with dostarlimab</measure>
    <time_frame>Up to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: AUC following administration of GSK3745417 in combination with dostarlimab</measure>
    <time_frame>Up to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2A: T1/2 following administration of GSK3745417 in combination with dostarlimab</measure>
    <time_frame>Up to Week 104</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part 1A: Participants receiving GSK3745417, Dose-escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3745417</intervention_name>
    <description>GSK3745417 will be administered.</description>
    <arm_group_label>Part 1A: Participants receiving GSK3745417, Dose-escalation Cohort</arm_group_label>
    <arm_group_label>Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dostarlimab</intervention_name>
    <description>Dostarlimab will be administered.</description>
    <arm_group_label>Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be more than or equal to (&gt;=)18 years of age.&#xD;
&#xD;
          -  Participants with advanced/recurrent solid tumors, who have progressed on, be&#xD;
             intolerant of, or ineligible for, all available therapies for which clinical benefit&#xD;
             has been established.&#xD;
&#xD;
          -  Histological or cytological documentation of an advanced solid tumor.&#xD;
&#xD;
          -  Participants must provide a fresh biopsy.&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version&#xD;
             1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.&#xD;
&#xD;
          -  Adequate organ function per protocol specifications.&#xD;
&#xD;
          -  Male or female participants.&#xD;
&#xD;
          -  Female participants are eligible to participate if they are not breastfeeding or&#xD;
             pregnant (or intend to breastfeed or become pregnant). Women of childbearing potential&#xD;
             must use a highly effective method of contraception.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic disease modifying or&#xD;
             immunosuppressive treatment within the last 2 years.&#xD;
&#xD;
          -  Concurrent medical condition requiring the use of systemic immunosuppressive treatment&#xD;
             within 28 days before the first dose of study treatment.&#xD;
&#xD;
          -  Current unstable liver or biliary disease.&#xD;
&#xD;
          -  History of vasculitis at any time prior to study treatment.&#xD;
&#xD;
          -  Evidence or history of significant active bleeding or coagulation disorder.&#xD;
&#xD;
          -  Active infection requiring systemic treatment, known human immunodeficiency virus&#xD;
             infection, or positive test for hepatitis B surface antigen or hepatitis C.&#xD;
&#xD;
          -  QT duration corrected for heart rate by Fridericia's formula (QTcF) more than (&gt;)450&#xD;
             milliseconds (msec) or QTcF &gt;480 msec for participants with bundle branch block.&#xD;
&#xD;
          -  Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel&#xD;
             disease, intra-abdominal abscess, or gastrointestinal obstruction.&#xD;
&#xD;
          -  Recent history of allergen desensitization therapy within 4 weeks of starting study&#xD;
             treatment.&#xD;
&#xD;
          -  History or evidence of cardiovascular (CV) risk&#xD;
&#xD;
          -  Recent (within the past 6 months) history of symptomatic pericarditis.&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, interstitial lung disease, or organizing&#xD;
             pneumonia, or evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
          -  History of (non-infectious) pneumonitis that required steroids or current pneumonitis.&#xD;
&#xD;
          -  Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural&#xD;
             effusions.&#xD;
&#xD;
          -  Prior treatment with the following agents:&#xD;
&#xD;
               1. Stimulator of Interferon Genes (STING) agonist at any time.&#xD;
&#xD;
               2. Anticancer therapy or investigational therapy or used an investigational device&#xD;
                  within 28 days or 5 half-lives of the drug, whichever is shorter.&#xD;
&#xD;
               3. Checkpoint inhibitors, including Programmed death receptor-1 (PD-1), Programmed&#xD;
                  death Ligand-1 (PD-L1), PD-L2 and Cytotoxic T-lymphocyte-associated antigen 4&#xD;
                  (CTLA-4) inhibitors within 28 days.&#xD;
&#xD;
               4. Prior radiation therapy: permissible if at least 1 non-irradiated measurable&#xD;
                  lesion is available for assessment according to RECIST version 1.1 or if a&#xD;
                  solitary measurable lesion was irradiated, objective progression is documented.&#xD;
&#xD;
          -  Pregnant and/or breast feeding participants or those who plan to become pregnant&#xD;
             and/or breastfeed.&#xD;
&#xD;
          -  Receipt of any live vaccine within 30 days of the start of study treatment.&#xD;
&#xD;
          -  Prior allogeneic or autologous bone marrow transplantation or other solid organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Major surgery less than or equal to (&lt;=)28 days before the first dose of study&#xD;
             treatment. Participants must have also fully recovered from any surgery (major or&#xD;
             minor) and/or its complications before initiating study treatment.&#xD;
&#xD;
          -  Participants with signs/symptoms suggestive of Coronavirus Disease-2019 (COVID-19)&#xD;
             within 14 days of study entry, or with known exposure to COVID-19 within 14 days prior&#xD;
             to study entry.&#xD;
&#xD;
          -  Participants are excluded from Part 2A of the study if they have known&#xD;
             hypersensitivity to dostarlimab or associated excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Funda Meric-Bernstam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jayesh Desai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Bedard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Antoine Italiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dong-Wan Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Byoung Chul Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Neeltje Steeghs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Catharina W. Menke - van der Houven van Oordt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Elena Garralda Cabanas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Moreno García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK3745417</keyword>
  <keyword>Dostarlimab</keyword>
  <keyword>Anti-Programmed death receptor-1 (PD-1)</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>First time in human</keyword>
  <keyword>Stimulator of Interferon Genes</keyword>
  <keyword>STING</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

